Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.YM BioSciences Reports Q2 Fiscal 2009 Results
“During the quarter we prepared to initiate our two randomized Phase II trials for nimotuzumab, which concentrate on two forms of cancer typically treated with radiation-containing regimens. These
“During the quarter we prepared to initiate our two randomized Phase II trials for nimotuzumab, which concentrate on two forms of cancer typically treated with radiation-containing regimens. These
The company has reported data from the first of three cohorts in an ascending multiple dose study of MSI-1436 (Study 102). Data from cohort 1, in which eight
Fourth Quarter Financial Highlights Consolidated net revenues increase by 33.9% to EUR68.5 million (+32.9% at constant exchange rates); EBITDA grow to EUR24.2 million, up 62.0% compared with the
The agreement resolves litigation that was pending in the US District Court of Texas with respect to certain Ethicon products. Ethicon is a subsidiary of Johnson & Johnson.
Mr Walker was most recently the chairman and CEO of Novacea, which merged with Transcept Pharmaceuticals in January 2009. Mr Walker currently serves on the board of directors
These positions were eliminated after Panacos sold bevirimat, and the company has refocused its efforts on its early stage programs. Dr McCallister has served in this capacity since
According to the company, results of initial studies outline the device’s ability to significantly improve drug delivery to mucous membranes such as those in the nose, intestine, eyes,
Mr Fincher’s primary areas of focus will be the medical markets in Mexico, Brazil, Argentina and Chile, although he will also work with all of the Latin American
Palatin has also earned a milestone payment of $2.5 million in connection with its collaboration and licensing agreement with AstraZeneca. Palatin anticipates receiving the $2.5 million in the
Most recently, Mr Shrewsbury served as chief medical officer and senior vice president of clinical development and regulatory affairs at Adamas Pharmaceuticals. Prior to that, Mr Shrewsbury served